Modulation of atherosclerosis, blood pressure and arterial elasticity by statins

Anjan Sinha, Jawahar L. Mehta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

It is well known that dyslipidemia and hypertension frequently coexist. There is increasing recognition of a mutually facilitative interaction between dyslipidemia and renin-angiotensin system (RAS) activation in the development of atherosclerosis. Both of these systems share many of the same properties in terms of activation of pro-inflammatory, pro-oxidant and pro-atherosclerosis pathways. Statins in particular have been shown to influence the biology of endothelial cells, vascular smooth muscle cells and constituents of the interstitial matrix, particularly fibroblasts. It is no wonder that concurrent therapy of dyslipidemia with statins enhances the effects of RAS inhibitors. Although the effects of statins on the regulation of determinants of vascular stiffness are not well defined, it is quite likely that these regulatory pathways will be influenced by dyslipidemia therapy, especially statins.

Original languageEnglish (US)
Pages (from-to)315-330
Number of pages16
JournalAdvances in Cardiology
Volume44
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Elasticity
Dyslipidemias
Atherosclerosis
Arterial Pressure
Renin-Angiotensin System
Vascular Stiffness
Vascular Smooth Muscle
Smooth Muscle Myocytes
Reactive Oxygen Species
Endothelial Cells
Fibroblasts
Hypertension
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Modulation of atherosclerosis, blood pressure and arterial elasticity by statins. / Sinha, Anjan; Mehta, Jawahar L.

In: Advances in Cardiology, Vol. 44, 2007, p. 315-330.

Research output: Contribution to journalArticle

@article{e6a163e9147a43b2b429e48a74d5516f,
title = "Modulation of atherosclerosis, blood pressure and arterial elasticity by statins",
abstract = "It is well known that dyslipidemia and hypertension frequently coexist. There is increasing recognition of a mutually facilitative interaction between dyslipidemia and renin-angiotensin system (RAS) activation in the development of atherosclerosis. Both of these systems share many of the same properties in terms of activation of pro-inflammatory, pro-oxidant and pro-atherosclerosis pathways. Statins in particular have been shown to influence the biology of endothelial cells, vascular smooth muscle cells and constituents of the interstitial matrix, particularly fibroblasts. It is no wonder that concurrent therapy of dyslipidemia with statins enhances the effects of RAS inhibitors. Although the effects of statins on the regulation of determinants of vascular stiffness are not well defined, it is quite likely that these regulatory pathways will be influenced by dyslipidemia therapy, especially statins.",
author = "Anjan Sinha and Mehta, {Jawahar L.}",
year = "2007",
doi = "10.1159/000096750",
language = "English (US)",
volume = "44",
pages = "315--330",
journal = "Advances in Cardiology",
issn = "0065-2326",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Modulation of atherosclerosis, blood pressure and arterial elasticity by statins

AU - Sinha, Anjan

AU - Mehta, Jawahar L.

PY - 2007

Y1 - 2007

N2 - It is well known that dyslipidemia and hypertension frequently coexist. There is increasing recognition of a mutually facilitative interaction between dyslipidemia and renin-angiotensin system (RAS) activation in the development of atherosclerosis. Both of these systems share many of the same properties in terms of activation of pro-inflammatory, pro-oxidant and pro-atherosclerosis pathways. Statins in particular have been shown to influence the biology of endothelial cells, vascular smooth muscle cells and constituents of the interstitial matrix, particularly fibroblasts. It is no wonder that concurrent therapy of dyslipidemia with statins enhances the effects of RAS inhibitors. Although the effects of statins on the regulation of determinants of vascular stiffness are not well defined, it is quite likely that these regulatory pathways will be influenced by dyslipidemia therapy, especially statins.

AB - It is well known that dyslipidemia and hypertension frequently coexist. There is increasing recognition of a mutually facilitative interaction between dyslipidemia and renin-angiotensin system (RAS) activation in the development of atherosclerosis. Both of these systems share many of the same properties in terms of activation of pro-inflammatory, pro-oxidant and pro-atherosclerosis pathways. Statins in particular have been shown to influence the biology of endothelial cells, vascular smooth muscle cells and constituents of the interstitial matrix, particularly fibroblasts. It is no wonder that concurrent therapy of dyslipidemia with statins enhances the effects of RAS inhibitors. Although the effects of statins on the regulation of determinants of vascular stiffness are not well defined, it is quite likely that these regulatory pathways will be influenced by dyslipidemia therapy, especially statins.

UR - http://www.scopus.com/inward/record.url?scp=33751109469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751109469&partnerID=8YFLogxK

U2 - 10.1159/000096750

DO - 10.1159/000096750

M3 - Article

C2 - 17075218

AN - SCOPUS:33751109469

VL - 44

SP - 315

EP - 330

JO - Advances in Cardiology

JF - Advances in Cardiology

SN - 0065-2326

ER -